Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

San Antonio, Texas 78229


This is an open-label, Phase I, dose escalation study to determine the recommended Phase 2 dose, maximum tolerated dose, and evaluate the safety and pharmacokinetic profile of ABBV-221 in participants with advanced solid tumors likely to exhibit elevated levels of Epidermal Growth Factor Receptor (EGFR).


Inclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 2. - Has a solid tumor likely to exhibit elevated levels of EGFR (e.g. head and neck squamous cell carcinoma, non-small cell lung cancer, triple negative breast cancer ,colorectal carcinoma and glioblastoma multiforme). - Has an archived, diagnostic tumor tissue available for analysis. - Has adequate hematologic, renal, cardiac and hepatic function. - Expanded Safety Cohort participants must have confirmed metastatic lung cancer and progressed after receiving prior platinum-containing chemotherapy. Exclusion Criteria: - Previously received an EGFR-directed monoclonal antibody within the past 4 weeks. - Has unresolved, clinically significant toxicities from prior anti-cancer therapy defined as > Grade 1 on Common Terminology Criteria for Adverse Events. - History of major immunologic reaction to any IgG containing agent. - Any medical condition which in the opinion of the investigator places the participant at an unacceptably high risk for toxicities.



Primary Contact:

Study Director
AbbVie Inc.

Backup Contact:


Location Contact:

San Antonio, Texas 78229
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.